Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies

INTRODUCTION: Extraintestinal manifestations (EIMs) in patients with Crohn’s disease (CD) are common and associated with additional morbidity. This study aimed to evaluate the effect of adalimumab therapy on EIM resolution and identify potential predictors of EIM resolution in adult and pediatric pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Louis, Edouard J., Reinisch, Walter, Schwartz, David A., Löfberg, Robert, Robinson, Anne M., Berg, Sofie, Wang, Anthony W., Maa, Jen-fue, Huang, Bidan, Pappalardo, Brandee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910478/
https://www.ncbi.nlm.nih.gov/pubmed/29516410
http://dx.doi.org/10.1007/s12325-018-0678-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910478/
https://www.ncbi.nlm.nih.gov/pubmed/29516410
http://dx.doi.org/10.1007/s12325-018-0678-0

Ejemplares similares